1-deoxytetradecasphinganine



Compound IDCDAMM00374
Common name1-deoxytetradecasphinganine
IUPAC name(2S,3R)-2-aminotetradecan-3-ol
Molecular formulaC14H31NO

Experimental data

Retention time55.774
Adduct[M+H]+
Actual mz230.248
Theoretical mz230.248
Error1.55
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score7.37

Identifiers and class information

Inchi keyWMUMHAZHWIUBPN-UONOGXRCSA-N
SmilesOC(CCCCCCCCCCC)C(N)C
SuperclassOrganic nitrogen compounds
ClassOrganonitrogen compounds

Pharmacokinetic properties

Number of descriptor values(#stars)1
Number of non-conjugated amine groups (#amine)1
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)13
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)0
Molecular weight (mol_MW)229.405
Computed dipole moment(dipole)2.073
Total solvent accessible surface area (SASA)619.016
Hydrophobic component of SASA (FOSA)535.482
Hydrophilic component of SASA (FISA)83.534
Pie component of the SASA (PISA)0
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1031.16
Number of hydrogen bond donors (donorHB)3
Number of hydrogen bond acceptors (accptHB)2.7
Free energy of solvation of dipole (dip^2/V)0.0041655
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0075548
Globularity descriptor (glob)0.797407
Predicted polarizability in cubic angstroms (QPpolrz)26.766
Predicted hexadecane/gas partition coefficient (QPlogPC16)8.991
Predicted octanol/gas partition coefficient (QPlogPoct)13.367
Predicted water/gas partition coefficient (QPlogPw)5.963
Predicted octanol/water partition coefficient (QPlogPo/w)3.038
Predicted aqueous solubility (QPlogS)-2.748
Conformation-independent predicted aqueous solubility (CIQPlogS)-1.526
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-5.536
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)398.699
Predicted brain/blood partition coefficient (QPlogBB)-0.697
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)202.57
Predicted skin permeability, log Kp (QPlogKp)-3.874
PM3 calculated ionization potential (IP(ev))9.402
PM3 calculated electron affinity (EA(eV))-2.548
Number of likely metabolic reactions (#metab)3
Prediction of binding to human serum albumin (QPlogKhsa)0.11
Predicted qualitative human oral absorption (HumanOralAbsorption)3
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)91.279
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)45.196
Number of nitrogen and oxygen atoms (#NandO)2
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P07327ADH1AAlcohol dehydrogenase alpha chainT65570SEA
P15144ANPEPAminopeptidase NT67272SEA
Q9NYA1SPHK1Sphingosine kinase 1T86014SwissTargetPrediction
P00813ADAAdenosine deaminaseT03661SEA
P0DJD9PGA5Pepsin AT17863SEA
P21453S1PR1Sphingosine 1-phosphate receptor Edg-1T13852SEA
Q9NRA0SPHK2Sphingosine kinase 2T31989SEA
Q99500S1PR3Sphingosine 1-phosphate receptor Edg-3T11241SEA
P43657LPAR6Lysophosphatidic acid receptor 6T13484SEA
O95136S1PR2Sphingosine 1-phosphate receptor Edg-5T47888SEA
O95977S1PR4Sphingosine 1-phosphate receptor Edg-6T17523SEA
Q9UBY5LPAR3Lysophosphatidic acid receptor Edg-7T95923SEA
Q99677LPAR4Lysophosphatidic acid receptor 4T58130SEA
O95749GGPS1GeranyltranstransferaseT86528SEA
Q4U2R8SLC22A6Solute carrier family 22 member 6 (by homology)T70680SEA
O60603TLR2Toll-like receptor 2T82078SEA
O95749GGPS1GeranyltranstransferaseT86528SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T65570DI0139Exposure to noxious substances harmful effect[ICD-11: NE61]P07327ADH1A
T67272DI0351Psoriasis[ICD-11: EA90]P15144ANPEP
T86014DI0321Ovarian cancer[ICD-11: 2C73]Q9NYA1SPHK1
T86014DI0353Psychoactive substances use disorder[ICD-11: 6C4G]Q9NYA1SPHK1
T03661DI0016Adaptive immunity immunodeficiency[ICD-11: 4A01]P00813ADA
T03661DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]P00813ADA
T03661DI0249Mature B-cell leukaemia[ICD-11: 2A82]P00813ADA
T13852DI0275Multiple sclerosis[ICD-11: 8A40]P21453S1PR1
T13852DI0419Ulcerative colitis[ICD-11: DD71]P21453S1PR1
T31989DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q9NRA0SPHK2
T11241DI0062Breast cancer[ICD-11: 2C60-2C6Y]Q99500S1PR3
T47888DI0419Ulcerative colitis[ICD-11: DD71]O95136S1PR2
T95923DI0146Fibrosis[ICD-11: GA14-GC01]Q9UBY5LPAR3
T95923DI0399Systemic sclerosis[ICD-11: 4A42]Q9UBY5LPAR3
T86528DI0057Bone paget disease[ICD-11: FB85]O95749GGPS1
T86528DI0237Low bone mass disorder[ICD-11: FB83]O95749GGPS1
T86528DI0267Mineral excesses[ICD-11: 5B91]O95749GGPS1
T86528DI0281Musculoskeletal disorder[ICD-11: FA00-FC0Z]O95749GGPS1
T70680DI0167Gout[ICD-11: FA25]Q4U2R8SLC22A6
T70680DI0206Inborn purine/pyrimidine/nucleotide metabolism error[ICD-11: 5C55]Q4U2R8SLC22A6
T70680DI0310Ocular disease[ICD-11: N.A.]Q4U2R8SLC22A6
T82078DI0346Prostate cancer[ICD-11: 2C82]O60603TLR2
T86528DI0057Bone paget disease[ICD-11: FB85]O95749GGPS1
T86528DI0237Low bone mass disorder[ICD-11: FB83]O95749GGPS1
T86528DI0267Mineral excesses[ICD-11: 5B91]O95749GGPS1
T86528DI0281Musculoskeletal disorder[ICD-11: FA00-FC0Z]O95749GGPS1

Copyright © 2025